BioSyent to Present at LD Micro New York Investor Conference
BioSyent (TSXV: RX) has announced its participation in the upcoming LD Micro Invitational XV Conference in New York City. The company's President and CEO, René Goehrum, is scheduled to deliver an in-person presentation on Thursday, April 10th at 12:00pm EDT.
In addition to the presentation, Goehrum will be available for one-on-one meetings with investors throughout April 10th. Interested investors who are registered conference attendees can schedule these private meetings through the official LD Micro Invitational XV online conference portal.
BioSyent (TSXV: RX) ha annunciato la sua partecipazione alla prossima LD Micro Invitational XV Conference a New York City. Il Presidente e CEO dell'azienda, René Goehrum, è programmato per una presentazione dal vivo giovedì 10 aprile alle 12:00 EDT.
Oltre alla presentazione, Goehrum sarà disponibile per incontri individuali con gli investitori durante tutto il 10 aprile. Gli investitori interessati che sono registrati come partecipanti alla conferenza possono programmare questi incontri privati tramite il portale ufficiale della conferenza online LD Micro Invitational XV.
BioSyent (TSXV: RX) ha anunciado su participación en la próxima LD Micro Invitational XV Conference en la ciudad de Nueva York. El Presidente y CEO de la compañía, René Goehrum, está programado para ofrecer una presentación en persona el jueves 10 de abril a las 12:00pm EDT.
Además de la presentación, Goehrum estará disponible para reuniones uno a uno con inversores a lo largo del 10 de abril. Los inversores interesados que estén registrados como asistentes a la conferencia pueden programar estas reuniones privadas a través del portal oficial de la conferencia online LD Micro Invitational XV.
BioSyent (TSXV: RX)는 뉴욕시에서 열리는 LD Micro Invitational XV Conference에 참여할 것이라고 발표했습니다. 회사의 사장 겸 CEO인 René Goehrum은 4월 10일 목요일 오후 12시 EDT에 대면 발표를 할 예정입니다.
발표 외에도 Goehrum은 4월 10일 동안 투자자들과의 일대일 회의를 위해 자리를 마련할 것입니다. 관심 있는 투자자들은 등록된 참석자로서 공식 LD Micro Invitational XV 온라인 회의 포털을 통해 이러한 개인 회의를 예약할 수 있습니다.
BioSyent (TSXV: RX) a annoncé sa participation à la prochaine LD Micro Invitational XV Conference à New York. Le Président et CEO de l'entreprise, René Goehrum, doit faire une présentation en personne le jeudi 10 avril à 12h00 EDT.
En plus de la présentation, Goehrum sera disponible pour des rencontres individuelles avec des investisseurs tout au long du 10 avril. Les investisseurs intéressés qui sont enregistrés en tant que participants à la conférence peuvent programmer ces réunions privées via le portail officiel de la conférence en ligne LD Micro Invitational XV.
BioSyent (TSXV: RX) hat seine Teilnahme an der bevorstehenden LD Micro Invitational XV Conference in New York City angekündigt. Der Präsident und CEO des Unternehmens, René Goehrum, wird am Donnerstag, den 10. April um 12:00 Uhr EDT eine persönliche Präsentation halten.
Zusätzlich zur Präsentation wird Goehrum am 10. April für Einzelgespräche mit Investoren zur Verfügung stehen. Interessierte Investoren, die als registrierte Konferenzteilnehmer teilnehmen, können diese privaten Meetings über das offizielle Online-Portal der LD Micro Invitational XV-Konferenz planen.
- None.
- None.
Mississauga, Ontario--(Newsfile Corp. - April 4, 2025) - BioSyent Inc. (TSXV: RX) ("BioSyent" or the "Company") announces that Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person at the LD Micro Invitational XV Conference in New York City on Thursday, April 10th at 12:00pm EDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on April 10th. These one-on-one meetings can be requested by registered attendees through the online conference portal: LD Micro Invitational XV.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
As of the date of this press release, the Company has 11,254,638 common shares outstanding.
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247398
FAQ
When and where is BioSyent (BIOYF) presenting at the LD Micro Conference?
How can investors meet with BioSyent (BIOYF) management at the LD Micro Conference?
Who will be representing BioSyent (BIOYF) at the LD Micro Invitational Conference?
What type of presentation format will BioSyent (BIOYF) deliver at the LD Micro Conference?
